MetaVia Advances DA-1726 Obesity Drug into Phase 1 Part 3

The latest update is out from MetaVia ( (MTVA) ).

On March 18, 2026, MetaVia Inc. announced that an Institutional Review Board at Clinical Pharmacology of Miami approved Part 3 of its Phase 1 clinical trial for DA-1726, its lead GLP-1 and glucagon dual agonist for obesity. The new 16-week study will explore higher-dose titration regimens to 48 mg and 64 mg in 40 obese but otherwise healthy adults, randomized 4:1 between active drug and placebo.

The trial is designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics, with primary endpoints centered on adverse events and secondary measures covering metabolic, glycemic, lipid, and body composition outcomes. Building on earlier cohorts where a 48 mg dose produced around 9% weight loss and improved cardiometabolic markers, the higher-dose Part 3 study is intended to further de-risk DA-1726, strengthen its differentiation versus currently marketed GLP-1 therapies, and support its progression into later-stage development.

The most recent analyst rating on (MTVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.

Spark’s Take on MTVA Stock

According to Spark, TipRanks’ AI Analyst, MTVA is a Neutral.

The score is held down primarily by persistent pre-revenue losses and worsening cash burn with a shrinking equity base, implying continued funding risk. Technicals also point to a clear downtrend despite oversold readings. Offsetting these are multiple positive clinical readouts and a recent financing that strengthens near-term liquidity and reduces listing-related risk.

To see Spark’s full report on MTVA stock, click here.

More about MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, with lead programs targeting obesity and Metabolic Dysfunction-Associated Steatohepatitis. Its pipeline includes DA-1726, a once-weekly dual GLP-1/glucagon oxyntomodulin analogue, and vanoglipel, a GPR119 agonist aimed at improving liver and metabolic health in MASH.

DA-1726 has shown best-in-class potential in earlier Phase 1 multiple ascending dose trials for weight loss, glucose control, and waist reduction, with pre-clinical models suggesting superior or comparable weight loss to leading GLP-1 agents while preserving lean body mass. Vanoglipel has demonstrated favorable effects on hepatic steatosis, inflammation, fibrosis, and glucose control in pre-clinical studies and direct hepatic action in a Phase 2a trial.

Average Trading Volume: 233,225

Technical Sentiment Signal: Strong Sell

Current Market Cap: $5.04M

For an in-depth examination of MTVA stock, go to TipRanks’ Overview page.